Enlivex Therapeutics (ENLV) 20-F 30 Apr 19 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document and Entity Information [Abstract]
Entity Registrant Name	Enlivex Therapeutics Ltd.
Entity Central Index Key	0001596812
Amendment Flag	false
Trading Symbol	ENLV
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	419,889

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents (notes 2d, 3)	$ 9,736	$ 9,005
Short term deposits	40
Prepaid expenses	288	14
Other receivables	213	95
Total Current Assets	10,277	9,114
Non-Current Assets
Restricted cash (note 2e)	56	27
Long-term prepaid expenses (note 2f)	16	11
Property and equipment, net (notes 2g, 4)	685	388
Total Non-Current Assets	757	426
TOTAL ASSETS	11,034	9,540
Current Liabilities
Accounts payable trade	173	37
Accrued expenses and other liabilities (note 5)	944	634
Payables to related parties (note 8)	13	25
Total Current Liabilities	1,130	696
Non-Current Liabilities
Retirement benefit obligations (note 2j)	6	7
Warrants (note 6)	192	344
Total Non-Current Liabilities	198	351
Commitments And Contingent Liabilities (note 7)
TOTAL LIABILITIES	1,328	1,047
SHAREHOLDERS’ EQUITY
Common stock of NIS 0.40 ($0.11) par value: (note 9) Authorized: 11,861,073 shares as of December 31, 2018 and 2017; Issued and outstanding: 3,509,405 and 3,509,344 as of December 31, 2018 and 2017;	396	396
Additional paid in capital	27,326	21,182
Foreign currency translation adjustments (note 2c)	(2,251)	(1,503)
Accumulated deficit	(16,289)	(12,047)
TOTAL SHAREHOLDERS' EQUITY	9,706	8,493
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	11,034	9,540
Series A Preferred Stock
SHAREHOLDERS’ EQUITY
Preferred stock	309	309
Series B Preferred Stock
SHAREHOLDERS’ EQUITY
Preferred stock	156	156
Series C Preferred Stock
SHAREHOLDERS’ EQUITY
Preferred stock	$ 59

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical)	Dec. 31, 2018$ / sharesshares	Dec. 31, 2018₪ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2017₪ / sharesshares
Common stock, par value | $ / shares	$ 0.11		$ 0.11
Common stock, shares authorized	11,861,073	11,861,073	11,861,073	11,861,073
Common stock, shares issued	3,509,405	3,509,405	3,509,344	3,509,344
Common stock, shares outstanding	3,509,405	3,509,405	3,509,344	3,509,344
Series A Preferred Stock
Preferred stock, par value | $ / shares	$ 0.11		$ 0.11
Preferred stock, authorized	3,146,815	3,146,815	3,146,815	3,146,815
Preferred stock, shares issued	3,059,730	3,059,730	3,059,730	3,059,730
Preferred stock, shares outstanding	3,059,730	3,059,730	3,059,730	3,059,730
Series B Preferred Stock
Preferred stock, par value | $ / shares	$ 0.11		$ 0.11
Preferred stock, authorized	3,485,703	3,485,703	3,485,703	3,485,703
Preferred stock, shares issued	1,373,804	1,373,804	1,373,804	1,373,804
Preferred stock, shares outstanding	1,373,804	1,373,804	1,373,804	1,373,804
Series C Preferred Stock
Preferred stock, par value | $ / shares	$ 0.11		$ 0.11
Preferred stock, authorized	3,146,815	3,146,815	3,146,815	3,146,815
Preferred stock, shares issued	525,171	525,171	525,171	525,171
Preferred stock, shares outstanding	525,171	525,171	525,171	525,171
NIS [Member]
Common stock, par value | ₪ / shares		₪ 0.40		₪ 0.40
NIS [Member] | Series A Preferred Stock
Preferred stock, par value | ₪ / shares		0.4		0.4
NIS [Member] | Series B Preferred Stock
Preferred stock, par value | ₪ / shares		0.4		0.4
NIS [Member] | Series C Preferred Stock
Preferred stock, par value | ₪ / shares		₪ 0.4		₪ 0.4

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues (note 2k)
Operating expenses:
Research and development expenses, net (notes 2l, 13a)	4,255	1,691	2,029
General and administrative expenses (note 13b)	1,044	480	793
Total operating expenses	5,299	2,171	2,822
Operating (loss)	(5,299)	(2,171)	(2,822)
Financial income (note 13c)	1,060	37	30
Financial expenses (note 13d)	(3)	(370)	(86)
Net (loss)	(4,242)	(2,504)	(2,878)
Other comprehensive gain (loss)
Interest on convertible notes			(67)
Exchange differences arising from translating financial statements from functional to presentation currency (note 2c)	(748)	336	93
Total other comprehensive gain (loss)	(748)	336	26
Total comprehensive (loss)	$ (4,990)	$ (2,168)	$ (2,852)
Basic & diluted (loss) per share (note 2o)	$ (1.40)	$ (0.94)	$ (1.03)
Weighted average number of shares outstanding	3,509,346	3,425,925	3,357,647

Statements of Changes in Shareh

Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Common stock		Preferred Stock	Additional paid in capital		Convertible notes	Currency translation adjustments	Accumulated deficit	Total
Balance at Dec. 31, 2015	$ 350			$ 4,839		$ 8,798	$ (1,932)	$ (6,598)	$ 5,457
Balance, shares at Dec. 31, 2015	3,068,184
Exercise of Options	$ 1			26					27
Exercise of Options, shares	10,545
Issuance of Common and Preferred Stock Series A in connection with conversion of convertible notes	$ 32		$ 309	8,524		(8,865)
Issuance of Common and Preferred Stock Series A in connection with conversion of convertible notes, shares	312,004		3,059,730
Interest on convertible notes						67		(67)
Stock based compensation				111					111
Other comprehensive gain							93		93
Net loss								(2,878)	(2,878)
Balance at Dec. 31, 2016	$ 383		$ 309	13,500			(1,839)	(9,543)	2,810
Balance, shares at Dec. 31, 2016	3,390,733		3,059,730
Issuance of Common Stock in connection with conversion of notes in 2016	$ 13			(13)
Issuance of Common Stock in connection with conversion of notes in 2016, shares	118,611
Issuance of Preferred Stock Series B for cash consideration of $8,249 net of $519 issuance costs			$ 156	7,574					7,730
Issuance of Preferred Stock Series B for cash consideration of $8,249 net of $519 issuance costs, shares			1,373,804
Stock based compensation				121					121
Other comprehensive gain							336		336
Net loss								(2,504)	(2,504)
Balance at Dec. 31, 2017	$ 396		$ 465	21,182			(1,503)	(12,047)	8,493
Balance, shares at Dec. 31, 2017	3,509,344		4,433,534
Exercise of Options		[1]			[1]					[1]
Exercise of Options, shares	61
Issuance of Preferred Stock Series C for cash consideration of $5,350 net of $156 issuance costs			$ 59	5,135					5,194
Issuance of Preferred Stock Series C for cash consideration of $5,350 net of $156 issuance costs, shares			525,171
Stock based compensation				1,009					1,009
Other comprehensive gain							(748)		(748)
Net loss								(4,242)	(4,242)
Balance at Dec. 31, 2018	$ 396		$ 524	$ 27,326			$ (2,251)	$ (16,289)	$ 9,706
Balance, shares at Dec. 31, 2018	3,509,405		4,958,705
[1]	Less than $1

Statements of Changes in Shar_2

Statements of Changes in Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Cash consideration	$ 5,350	$ 8,249
Issuance costs	$ 156	$ 519

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018		Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net (loss)	$ (4,242)		$ (2,504)	$ (2,878)
Adjustments required to reflect net cash used in operating activities:
Depreciation	121		83	58
Share-based compensation	1,009		121	111
Accrued income on deposits				(2)
Issuance expenses related to warrants exercisable into shares			19
Changes in values of warrants exercisable into shares	(132)
Changes in operating asset and liability items:
(Increases) decrease in prepaid expenses	(293)		33	108
(Increase) decrease in other receivables	(130)		(40)	465
Increase (decrease) in accounts payable trade	145		1	(42)
Increase (decrease) in accrued expenses and other liabilities	372		(11)	(10)
(Decrease) in payables to related parties	(11)		(6)
Net cash (used in) operating activities	(3,161)		(2,304)	(2,190)
Cash flows from investing activities
Investment in restricted cash	(32)			(5)
Purchase of property and equipment	(461)		(130)	(182)
Investment in short-term bank deposits	(40)
Release of short-term bank deposits, net				5,011
Net cash provided by (used in) investing activities	(533)		(130)	4,824
Cash flow from financing activities
Proceeds from issuance of preferred stock and warrants, net	5,194		8,055
Proceeds from exercise of options		[1]		27
Net cash provided by financing activities	5,194		8,055	27
Increase in cash and cash equivalents	1,500		5,621	2,661
Cash and cash equivalents - beginning of year	9,005		3,020	262
Exchange rate differences on cash and cash equivalents	(769)		364	97
Cash and cash equivalents - end of year	9,736		9,005	3,020
Non-cash transactions:
Issuance of Common and Preferred Stock in connection with conversion of Convertible Notes and accrued interest			7	8,865
Interest on convertible notes				67
Supplemental disclosures of cash flow information:
Cash paid for taxes
Cash received for interest	$ 138		$ 37	$ 30
[1]	Less than $1

General Information

General Information	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL INFORMATION	NOTE 1 – GENERAL INFORMATION a. General Enlivex Therapeutics R&D Ltd. (the" Company"), headquartered in Nes Ziona Israel, was incorporated under the laws of Israel and commenced operations on September 25, 2005. On March 24, 2019 the Company changed its name from Enlivex Therapeutics Ltd. to Enlivex Therapeutics R&D Ltd. Since inception, the Company has been engaged in the development of an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions which involve over-expression or hyper-expression of cytokines (Cytokine Release Syndrome) such as CAR-T (Chimeric Antigen Receptor) cancer treatment procedures, Graft-versus-Host disease (GvHD) resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis, and other disorders. The development is based on the discoveries of Professor Dror Mevorach, an expert on clearance of dying (apoptotic) cells, in his laboratory in the Hadassah University Hospital ("Hadassah"). On November 19, 2018, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Bioblast Pharma Ltd., a company organized under the laws of the State of Israel ("Bioblast") and which shares are listed for trading on the Nasdaq Stock Market, Inc., and Treblast Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Bioblast ("Merger Sub"), pursuant to which Merger Sub will merge (the "Merger") with and into the Company, with the Company surviving as the continuing company in the Merger and becoming wholly owned by Bioblast upon the terms and subject to the conditions set forth in the Merger Agreement. Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger each outstanding ordinary share and all outstanding options of the Company will be converted into Bioblast ordinary shares and options. On March 25, 2019, Merger Sub and the Company consummated the Merger, and the Company became a wholly owned subsidiary of Bioblast. Upon completion of the Merger, the name of Bioblast changed to Enlivex Therapeutics Ltd., and Bioblast has been admitted for continued listing on the Nasdaq Capital Market under the new symbol "ENLV". Each outstanding ordinary share and option of the Company was converted into approximately 0.04841 ordinary shares and options of Bioblast, subsequently, the Company's equity holders owned approximately 96% of Bioblast's issued and outstanding equity on a fully dilutes basis in accordance with the treasury stock method. b. Financial resources The Company devotes substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue for the foreseeable future. The Company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations. The Company's accumulated deficit aggregated $16,289 through December 31, 2018. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. The Company's management plans to finance its operations with issuances of the Company's equity securities and, in the longer term, revenues. There are no assurances, however, that the Company will be successful in obtaining an adequate level of financing needed for the long-term development. The Company's ability to continue to operate in the long term is dependent upon additional financial support. The Company's management and board of directors believes that its current cash sources will enable the continuance of the Company's activities for at least a year of the date the financial statements are issued with no need for additional fundraising.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation The Company's financial statements as of December 31, 2018 and 2017, and for each of the years in the three-year period ended December 31, 2018, have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). The significant accounting policies described below have been applied on a consistent basis for all years presented. The financial statements have been prepared on the basis of historical cost, subject to adjustment of financial assets and liabilities to their fair value through profit or loss. The Company classifies its expenses on the statement of comprehensive loss based on the operating characteristics of such expenses. b. Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make accounting estimates, judgments and assumptions, it also requires that management exercise its judgment in applying the Company's accounting policies. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. c. Functional currency and translation to the reporting currency The functional currency of the Company is the New Israeli Shekel ("NIS"), which is the local currency in which the entity operates. The financial statements of the Company were translated into U.S. dollars in accordance with ASC 830, "Foreign Currency Matters". Accordingly, assets and liabilities were translated from local currencies to U.S. dollars using yearend exchange rates, equity items were translated at the exchange rates of the date of the equity transaction, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments (which result from translating an entity's financial statements into U.S. dollars if its functional currency is different than the U.S. dollar) are reported in other comprehensive income (loss). Balances denominated in, or linked to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of income, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. The following table presents data regarding the dollar exchange rate: U.S. $ Exchange rate In Points (*) 1 $ = NIS At the end of: 2018 101.2 3.748 2017 100.4 3.467 2016 100.0 3.845 Increase (decrease) during the year: 2018 0.8 % 8.1 % 2017 0.4 % (9.8 )% 2016 (1.2 )% (1.5 )% (*) Based on the Index for December of each year, on the basis of 2016 Index = 100 points. d. Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. e. Restricted cash: Restricted cash held in interest bearing saving accounts which are used as a security for the Company's facility leasehold bank guarantee. f. Non-current prepaid expenses: Non-current prepaid expenses consist of non-current lease deposits as security for the Company's motor vehicles leases. g. Property and equipment Property and equipment are stated at historical cost less depreciation. Assets are depreciated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows: % Computers 33 Office furniture and equipment 7 Leasehold improvements 10 Laboratory equipment 15-33 h. Impairment of non-financial assets The long-lived assets of the Company are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2018, 2017, and 2016, no impairment losses have been identified. i. Stock-based compensation The Company recognizes equity-based compensation expenses for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with FASB ASC Topic 718, Stock Compensation ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The option pricing model requires a number of assumptions. There is no active external or internal market for the Company's common shares, consequently the Company utilized third-party valuations to estimate the fair value of its Ordinary Shares. For the estimation of the expected volatility of the Company's share price, the Company used the historical volatility of comparable companies in the industry with characteristics similar to the Company, including stage of product development and focus on the life science industry. The expected term of options granted represents the period of time that options granted are expected to be outstanding, the company uses management's estimates for the expected term of options due to insufficient readily available historical exercise data. The risk-free interest rate is based on the yield rates of U.S. Government Treasury Bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The Company accounts for stock options issued to non-employees in accordance with ASC Topic 505-50 "Equity -Based Payment to Non-Employees" and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Share-based awards to non-employees are remeasured at each reporting date and compensation costs are recognized as services are rendered. The Company believes that the fair value of these awards is more reliably measurable than the fair value of the services rendered. j. Employees benefits Post-employment benefits - Short term employee benefits k. Revenue Recognition The Company has not yet generated any revenue from product sales. l. Research and development expenses Research and development expenses are charged to the statement of operations and comprehensive loss as incurred and consist of salaries, stock-based compensation, benefits and other personnel-related costs, fees paid to consultants, clinical trials, patent costs and facilities and overhead costs. As of December 31, 2018, the Company has not yet capitalized development expenses. m. Patents The Company expenses all costs associated with patents for product candidates under development as incurred. As a result of the Company's research and development efforts, the Company is applying for a number of patents to protect proprietary technology and inventions. To date, the Company has not capitalized patent costs. The Company has recorded a charge to operations of approximately $242, $219 and $87 for the years ended December 31, 2018, 2017 and 2016, respectively, related to its patents' costs. n. Income taxes The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes". This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. As the Company is currently engaged primarily in development activities and is not expected to generate taxable income in the foreseeable future, the Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2018, the Company provided a liability of $222, see note 5, for uncertain tax positions related to tax withholding matters from prior years. The Company does not expect that the amounts of uncertain tax positions will change significantly within the next year. o. Loss per share Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, "Earnings per Share." All outstanding preferred stock, options and warrants for the years ended December 31, 2018, 2017 and 2016 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all years presented. For the years ended December 31, 2018, 2017 and 2016 the total weighted average number of shares related to outstanding potential shares excluded from the calculations of diluted net loss per share were 8,638,789, 4,926,621and 3,707,654, respectively. The following data shows the amounts used in computing income (loss) per share and the effect on income (loss): Year ended December 31, Basic and diluted (loss) per share: 2018 2017 2016 (Loss) income from continuing operations $ (4,242 ) $ (2,503 ) $ (2,878 ) Interest on convertible notes - (67 ) Interest of 6% to Cumulative Preferred Stock (659 ) (717 ) (497 ) $ (4,901 ) $ (3,220 ) $ (3,442 ) Number of common shares at the beginning of the year 3,509,344 3,390,733 3,068,184 Stock options exercised 2 - 3,958 Common shares issued in connection with conversion of convertible notes - 35,192 285,505 Number of shares used in per share computation 3,509,346 3,425,925 3,357,647 Basic net income (loss) per share $ (1.40 ) $ (0.94 ) $ (1.03 ) p. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash. Cash and cash equivalents are invested in major banks in Israel. Such deposits in Israel are not insured. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company has no foreign exchange contracts or any other hedging arrangements. q. Fair value of financial instruments The Company applies ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. The financial instruments presented on the balance sheet at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - inputs other than quoted prices included within level 1 that are observable either directly or indirectly. Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). The Company's warrants exercisable into shares liability are classified as level 3 in the fair value hierarchy, and measured at fair value on a recurring basis. r. Comprehensive income (loss) Comprehensive loss is the change in stockholders' equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general purpose financial statements. The Company's other comprehensive income (loss) is currently comprised of gains or losses resulting from translation adjustments which result from translating the Company's financial statements into U.S. dollars when its functional currency is different than the U.S. dollar. s. New standards and interpretations In February 2018, the FASB issued ASU 2018-02, I ncome Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In May 2017, the FASB issued ASU No. 2017-09, Compensation (Topic 718) s. New standards and interpretations (cont.) In August 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS	NOTE 3 – CASH AND CASH EQUIVALENTS December 31, 2018 2017 Cash held in banks $ 1,029 $ 498 Bank deposits in U.S.$ (annual average interest rates 1.81% and 1.37%) 8,707 8,507 $ 9,736 $ 9,005

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: December 31, 2018 2017 Cost: Laboratory equipment $ 797 $ 533 Computers 86 80 Office furniture & equipment 58 55 Leasehold improvements 228 126 1,169 794 December 31, 2018 2017 Accumulated depreciation: Laboratory equipment 331 266 Computers 62 51 Office furniture & equipment 13 10 Leasehold improvements 78 79 484 406 Depreciated cost $ 685 $ 388 For the years ended December 31, 2018, 2017 and 2016, depreciation expenses were $121, $83 and $58, respectively.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES December 31, 2018 2017 Vacation, convalescence and bonus accruals $ 211 $ 133 Employees and payroll related 158 104 Tax provision for uncertain tax position 222 240 Accrued expenses and other 353 157 $ 944 $ 634

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
WARRANTS	NOTE 6 – WARRANTS On September 15, 2017 the Company issued shares of Series B Preferred Stock and warrants exercisable into shares of Series B Preferred Stock, see note 9c. Year ended December 31, 2018 2017 Balance at January 1 $ 344 $ - Exchange differences arising from translation to presentation currency (20 ) Fair value of warrants at issuance date 344 Changes in values of warrants exercisable into shares liability (132 ) - Balance at December 31 $ 192 $ 344 The fair value of warrants granted was valued by using the OPM pricing model. Fair values were estimated using the following assumptions for the warrants call option: Year ended December 31, 2018 2017 Dividend yield - - Expected yearly volatility 75.8 % 75.83 % Annual risk-free interest 2.74 % 1.39 % Expected life 1 month 2 years

Commitments and contingent liab

Commitments and contingent liabilities	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 7 – COMMITMENTS AND CONTINGENT LIABILITIES 1) Obligation to pay royalties to the State of Israel The Company is required to pay royalties to the State of Israel (represented by the Israel Innovation Authority), computed on the basis of proceeds from the sale or license of products which development was supported by State grants. In accordance with the terms of the financial participation, the State is entitled to royalties on the sale or license of any product which development was supported with State participation. These royalties are generally 3% - 5% of sales until repayment of 100% of the grants (linked to the dollar) received by the Company plus annual interest at the LIBOR rate. The aggregate contingent obligation payable by the Company as of December 31, 2018 was approximately $3,973 which represents the gross amount of grants actually received by the Company from the Israel Innovation Authority, including accrued interest as of December 31, 2018. As of December 31, 2018, the Company had not paid any royalties to the Israel Innovation Authority. 2) Lease agreements - On September 17, 2015 the Company entered into a rental agreement for approximately 283 square meters of offices and laboratory space in the biotechnology park in the Hadassah University Hospital. The rental agreement is for a period of 4 years commencing December 31, 2015 and can be extended by an additional period of 4 years. The monthly rental and management fees are NIS 22 ($6) linked to the Israeli CPI. To secure the liability of the Company for the new lease, the Company provided the lessor a bank guarantee in an amount of approximately $20 thousand (NIS 75 thousand). - On July 30, 2018 the Company entered into a rental agreement for approximately 420 square meters of offices and laboratory space in the biotechnology park in Ness Ziona. The rental agreement is for a period of 5 years commencing September 1, 2018 and can be extended by an additional period of 5 years. The monthly rental and management fees are NIS 26 ($7). To secure the liability of the Company for the new lease, the Company provided the lessor a bank guarantee of approximately NIS 115 ($31). - The Company has entered into three motor vehicles operating lease agreements. Future minimum lease commitments under the abovementioned operating leases as of December 31, 2018, are as follows: 2019 $ 185 2020 115 2021 97 2022 83 2023 62 $ 542

Transactions with Related Parti

Transactions with Related Parties	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
TRANSACTIONS WITH RELATED PARTIES	NOTE 8 – TRANSACTIONS WITH RELATED PARTIES Expenses (income): Year ended December 31, 2018 2017 2016 Benefits to related parties: Compensation to non-employees directors $ - $ - $ 21 Share based Compensation to non-employees directors $ 73 $ (29 ) 47 Other related parties expenses $ 50 $ - $ - Other Comprehensive loss - interest on convertible notes $ - $ - $ 67 Key management compensation: Key management includes directors (executive and non-executive) and executive officers. Year ended December 31, 2018 2017 2016 Salaries and employee benefits $ 500 $ 517 $ 520 Share-based compensation 745 51 62 $ 1,245 $ 568 $ 582

Equity

Equity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
EQUITY	NOTE 9 – EQUITY a) Shares of Common Stock confer upon their holders the right to participate and vote in general stockholders' meetings, to share in the distribution of dividends if declared by the Company and the right to receive assets of the Company upon its liquidation. Shares of Preferred Stock confer on their holders all rights accruing to holders of Common Stock, and, in addition, bear certain conversion and preference rights. Preferred A, Preferred B and Preferred C Stock also confer upon their holders the right to receive an annual dividend amount equal to the original issue price of each Preferred Stock plus a cumulative preference of 6% of the original issue price per annum compounded annually until the lapse of two years from their issuance date. Accumulated unpaid dividends to series A, series B and series C Convertible Preferred Stock holders as of December 31, 2018, 2017 and 2016 were $1,872, $1,213 and $496, respectively. b) On September 12, 2018 the Company issued 520,263 shares of Series C Preferred Stock for cash consideration of $5,300. During December 2018 the Company issued additional 4,908 shares of Series C Preferred Stock for cash consideration of $50. Issuance costs in relation to the financing round in the amount of $156 were allocated to additional paid in capital. c) On September 15, 2017 and October 20, 2017, the Company issued a total of 1,373,804 shares of Series B Preferred Stock of the Company, and a total of 1,773,398 warrants exercisable into shares of Series B Preferred Stock for a total cash consideration of $8,550 comprising of: Shares of Series B Preferred Stock $ 7,730 Issuance costs allocated to Preferred Stock 519 8,249 Fair value attributed to the investors' warrants 301 $ 8,550 The warrants can be exercised only (i) post the consummation of a public listing of the Company's shares on an Asian-Pacific stock exchange, with aggregate proceeds of at least $25,000 and a price per share reflecting a company pre-money Company valuation of at least $200,000; (ii) post the consummation of an M&A transaction with a Asian-Pacific company reflecting a Company valuation of at least $200,000; or (iii) post the closing of a licensing agreement between the Company and an Asian-Pacific party that provides for an initial payment to the Company of at least $25,000. (together, i, ii and iii, the "Exercise Event"). The warrants will be canceled and nullified prior to its expiration date upon the consummation of a public listing of the Company's shares on a non-Asian-Pacific stock exchange or upon the consummation of an M&A transaction with a non-Asian-Pacific company. If exercised, each warrant converts into 1 share of Series B Preferred Stock of the Company at an exercise price of $6.22 per share subject to the fulfillment of an Exercise Event. The warrants will expire at the earlier of 36 months from the issuance date or an Exercise Event as defined in the warrant agreements, the exercise period may be extended under certain conditions in the case the warrants have not been canceled and nullified. The warrants may be exercised via a cashless exercise mechanism, whereby the number of shares the value of which equals the exercise premium in cash will be deducted from the number of shares to be issued upon exercise of the warrant. In addition, the number of warrants outstanding will be customarily adjusted subject to certain events specified in the warrant agreement, such as stock dividend, share split and others. The Company issued additional warrants in settlement of issuance costs to purchase 48,204 shares of Series B Preferred Stock at $6.22 per warrant, subject to certain adjustments, for a period of 7 years. These warrants may also be exercised on a cashless basis. The fair value of these warrants issued at grant date was $37 and was considered as additional issuance costs. In accordance with ASC 815: "Derivatives and Hedging", one of the characteristics of a derivative is that its terms require or permit net settlement. Accordingly, all warrants were classified as a non-current liability measured at fair value. The Company first allocated the proceeds of the issuance to the warrants; the remaining proceeds were allocated to the shares and were recorded to equity. The total issuance costs in relation to the financing round in the amount of $538 were allocated between the warrants and the shares in proportion to the allocation of the proceeds. The portions of the issuance costs in the amount of $19 that were allocated to the warrants and recorded as financial expense in the Company's statement of comprehensive loss. The portions of the issuance costs that were allocated to the Preferred Stock of $519, were recorded to the additional paid in capital in the Company's balance sheet. d) On February 1, 2016 the entire aggregate principal amount of convertible notes issued by the Company in 2014 with all accrued and unpaid interest thereon, in the amount of $8,865 was converted into 3,059,730 shares of Series A convertible preferred stock. 312,004 and 118,611 shares of common stock have been issued to several shareholders, who were entitled to certain anti-dilution rights on February 1, 2016 and September 14, 2017, respectively.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 10 – SHARE-BASED COMPENSATION a) Stock option plan – general Options granted under the Equity Incentive Plans and agreements expire after ten years from the date of grant. Upon termination of the optionee's employment or other relationship with the Company, options cease vesting, vested options forfeit. Ordinary shares underlying options that are canceled or not exercised within the option term become available for future grant. In 2007, the Company adopted its 2007 Incentive Compensation Plan (the "Equity Incentive Plan") under which 48,466shares were authorized for issuance to its employees, outside directors and consultants. In 2014, the Company adopted its Global Share Incentive Plan (2014) (the "2014 Equity Incentive Plan") under which 1,835,204shares are authorized for issuance to its employees, officers, directors and consultants. As of December 31, 2018, none of the shares under the 2007 Equity Incentive Plan and 23,182shares under the 2014 Equity Incentive Plan were available for future grant. b) Employees' and directors stock options The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the periods indicated: Year ended December 31, 2018 2017 2016 Weighted Average Risk-free interest rate 2.88 % 2.25 % 1.34 % Dividend yield - - - Weighted Average Volatility factor 74.91 % 73.31 % 72.57 % Weighted Average Expected life of the options 6 6 6 The following table contains additional information concerning options granted to employees and directors under the existing stock-option plans: For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of the year 974,272 $ 4.54 453,973 $ 2.69 483,482 $ 2.69 Granted 271,355 $ 5.78 590,839 $ 5.78 11,667 $ 2.69 Forfeited and expired (162,543 ) $ 4.96 (70,540 ) $ 2.69 (30,631 ) $ 2.69 Exercised (61 ) $ 2.69 - $ - (10,545 ) $ 2.69 Outstanding at end of the year 1,083,023 $ 4.75 974,272 $ 4.54 453,973 $ 2.69 Exercisable at end of the year 457,721 $ 3.72 243,373 $ 2.69 143,974 $ 2.69 Following is a summary of changes in nonvested shares granted to employees and directors: For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Balance at beginning of the year 730,899 $ 5.37 309,999 $ 2.69 444,241 $ 2.69 Granted 271,355 $ 5.78 590,839 $ 5.78 11,667 $ 2.69 Vested during the year (217,733 ) $ 4.75 (102,724 ) $ 2.69 (115,278 ) $ 2.69 Forfeited during the year (159,219 ) $ 5.16 (67,215 ) $ 2.69 (30,631 ) $ 2.69 Balance at end of the year 625,302 $ 5.58 730,899 $ 5.37 309,999 $ 2.69 The weighted-average fair value at grant date of the options granted 2018, 2017 and 2016 were $5.78, $ 0.207 and $ 0.826. The total unrecognized estimated compensation cost related to non-vested employees' and directors' stock options granted until December 31, 2018 was $1,274, which is expected to be recognized over a weighted average period of 1.82 years. c) Consultants' stock options The estimated fair value of stock option awards was determined using the Black-Scholes option valuation model with the following weighted-average assumptions during the periods indicated: Year ended December 31, 2018 2017 2016 Weighted Average Risk-free interest rate 2.55 % 2.25 % - Dividend yield - - - Weighted Average Volatility factor 75.23 % 73.31 % - Weighted Average Expected life of the options 6 6 - The following table contains additional information concerning options granted to consultants under the existing stock-option plans: For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of the year 684,506 $ 3.51 398,937 $ 2.69 398,937 $ 2.69 Granted 33,889 $ 6.40 285,569 $ 4.54 - $ - Forfeited and expired - $ - - $ - - $ - Exercised - $ - - $ - - $ - Outstanding at end of the year 718,395 $ 3.72 684,506 $ 3.51 398,937 $ 2.69 Exercisable at end of the year 568,921 $ 2.89 529,586 $ 2.69 398,937 $ 2.69 Following is a summary of changes in nonvested shares granted to consultants: For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Balance at beginning of the year 154,920 $ 6.20 - $ - 398,937 $ 2.69 Granted 33,889 $ 6.40 285,569 $ 4.54 - $ - Vested during the year (39,335 ) $ 6.20 (130,649 ) $ 2.69 (398,937 ) $ 2.69 Forfeited during the year - $ - - $ - - $ - Balance at end of the year 149,474 $ 6.20 154,920 $ 6.20 - $ - The total unrecognized estimated compensation cost related to non-vested consultants' stock options granted until December 31, 2018 was $690, which is expected to be recognized over a weighted average period of 2.9 years. d) Set forth below is data regarding the range of exercise prices and remaining contractual life (in years) for all options outstanding at December 31, 2018: exercise price Number of options outstanding Remaining contractual Life (in years) No. of options exercisable $ 1.86 533 0.8 533 $ 2.69 736,034 6.0 668,382 $ 2.69 35,895 1.5 35,895 $ 2.69 7,310 7.2 3,655 $ 2.69 137,814 8.2 132,440 $ 2.69 16,622 9.0 16,622 $ 6.22 561,966 9.0 169,115 $ 6.22 73,504 9.1 - $ 6.22 53,192 9.6 - $ 6.22 3,147 9.7 - $ 6.22 108,928 9.8 - $ 2.69 49,867 9.8 - $ 10.12 2,421 9.9 - $ 6.22 14,185 9.9 - 1,801,418 1,026,642 The total intrinsic value of options granted and options exercised during 2018 was $963 and $0, respectively. e) The following table summarizes share-based compensation expenses related to grants under the Equity Incentive Plan included in the statements of operations: Year ended December 31, 2018 2017 2016 Research & development $ 862 $ 123 $ 21 General & administrative 147 (2 ) 90 Total $ 1,009 $ 121 $ 111

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 11 – TAXES ON INCOME a. The Israeli corporate tax rate was 25% in 2016. As of January 1, 2017, the corporate tax rate was reduced to 24% and to 23% as of January 1, 2018 and onwards. b. The Company has not been assessed for tax purposes since its incorporation. Tax assessments through the year ended December 31, 2013 are deemed to be final. c. As of December 31, 2018, the Company had carry-forwards losses amounting to approximately $12,050. These carried forward losses have no expiration date. d. The components of the provision for income taxes are as follows: Year ended December 31, 2018 2017 2016 Current tax $ - $ - $ - Deferred tax - - - Provision for income taxes, net $ - $ - $ - e. Reconciliation of the theoretical tax expenses: Year ended December 31, 2018 2017 2016 Loss before taxes $ 4,242 $ 2,503 $ 2,878 Statutory tax rate 23 % 24 % 25 % Tax benefit 976 601 719 Permanent differences (237 ) (30 ) (28 ) Valuation allowance (778 ) (501 ) (652 ) Differences in tax rate - (36 ) (65 ) Translation differences 39 (34 ) 26 Tax expenses $ - $ - $ - f. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. As of December 31, 2018, the Company has provided full valuation allowance in respect of deferred tax assets. Management currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the loss carry-forward and other temporary differences will not be realized in the foreseeable future. Components of the Company’s deferred tax liabilities and assets are as follows: Year ended December 31, 2018 2017 2016 Tax assets in respect of: $ $ $ Accrued employees benefits 31 18 17 Research and development expenses 615 379 414 Net loss carry forward 2,771 2,242 1,707 Total deferred tax assets 3,417 2,639 2,138 Less - valuation allowance (3,417 ) (2,639 ) (2,138 ) Deferred tax assets $ - $ - $ -

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 12 – FAIR VALUE MEASUREMENT The Company’s financial assets measured at fair value on a recurring basis, consisted of the following types of instruments as of December 31, 2018, 2017 and 2016: December 31, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 9,736 $ 9,736 $ - $ - Short term deposits 40 40 - - Restricted cash 56 56 - - Total financial assets $ 9,832 $ 9,832 $ - $ - Warrants $ 192 $ - $ - $ 192 Total financial liabilities $ 192 $ - $ - $ 192 December 31, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 9,005 $ 9,005 $ - $ - Restricted cash 27 27 - - Total financial assets $ 9,032 $ 9,032 $ - $ - Warrants $ 344 $ - $ - $ 344 Total financial liabilities $ 344 $ - $ - $ 344 December 31, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,020 $ 3,020 $ - $ - Restricted cash 25 25 - - Total financial assets $ 3,045 $ 3,045 $ - $ -

Supplementary Financial Stateme

Supplementary Financial Statement Information	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 13 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION a. Research and development expenses – net Year ended December 31, 2018 2017 2016 Payroll and related expenses $ 1,317 $ 593 $ 732 Research and development services 1,237 493 832 Patent-related expenses 242 219 87 Share Based Compensation 862 123 21 Depreciation 121 83 58 Other 476 180 203 4,255 1,691 1,933 Israel Innovation Authority participation in research and development costs and royalties payable - - 96 $ 4,255 $ 1,691 $ 2,029 b. General and administrative expenses Year ended December 31, 2018 2017 2016 Payroll expenses and management fees $ 525 $ 365 $ 373 Professional fees 208 70 211 Office maintenance and other 108 23 96 Share Based Compensation 147 (2 ) 90 Travel Expenses 57 24 23 $ 1,045 $ 480 $ 793 c. Financial income Year ended December 31, 2018 2017 2016 Interest income $ 138 $ 37 $ 30 Exchange differences, net 790 - - Net change in fair value warrants 132 - - $ 1,060 $ 37 $ 30 d. Financial expenses Year ended December 31, 2018 2017 2016 Issuance expenses related to warrants $ - $ 19 $ - Exchange differences, net - 350 84 Bank commissions 3 1 2 $ 3 $ 370 $ 86

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet Date	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 14 – EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE The Company evaluated all events and transactions that occurred subsequent to the balance sheet date and prior to the date on which these financial statements were issued, and determined that the following events necessitated disclosure : On March 25, 2019 pursuant to the Merger Agreement, the Company consummated a Merger and became a wholly owned subsidiary of Bioblast Pharma Ltd. as described in note 1.a. On March 24, 2019 the Company changed its name from Enlivex Therapeutics Ltd. to Enlivex Therapeutics R&D Ltd. and Bioblast Pharma Ltd. changed its name to Enlivex Therapeutics Ltd.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of presentation	a. Basis of presentation The Company's financial statements as of December 31, 2018 and 2017, and for each of the years in the three-year period ended December 31, 2018, have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). The significant accounting policies described below have been applied on a consistent basis for all years presented. The financial statements have been prepared on the basis of historical cost, subject to adjustment of financial assets and liabilities to their fair value through profit or loss. The Company classifies its expenses on the statement of comprehensive loss based on the operating characteristics of such expenses.
Use of estimates	b. Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make accounting estimates, judgments and assumptions, it also requires that management exercise its judgment in applying the Company's accounting policies. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Functional currency and translation to the reporting currency	c. Functional currency and translation to the reporting currency The functional currency of the Company is the New Israeli Shekel ("NIS"), which is the local currency in which the entity operates. The financial statements of the Company were translated into U.S. dollars in accordance with ASC 830, "Foreign Currency Matters". Accordingly, assets and liabilities were translated from local currencies to U.S. dollars using yearend exchange rates, equity items were translated at the exchange rates of the date of the equity transaction, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments (which result from translating an entity's financial statements into U.S. dollars if its functional currency is different than the U.S. dollar) are reported in other comprehensive income (loss). Balances denominated in, or linked to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of income, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. The following table presents data regarding the dollar exchange rate: U.S. $ Exchange rate In Points (*) 1 $ = NIS At the end of: 2018 101.2 3.748 2017 100.4 3.467 2016 100.0 3.845 Increase (decrease) during the year: 2018 0.8 % 8.1 % 2017 0.4 % (9.8 )% 2016 (1.2 )% (1.5 )% (*) Based on the Index for December of each year, on the basis of 2016 Index = 100 points.
Cash and cash equivalents	d. Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
Restricted cash	e. Restricted cash: Restricted cash held in interest bearing saving accounts which are used as a security for the Company's facility leasehold bank guarantee.
Non-current prepaid expenses	f. Non-current prepaid expenses: Non-current prepaid expenses consist of non-current lease deposits as security for the Company's motor vehicles leases.
Property and equipment	g. Property and equipment Property and equipment are stated at historical cost less depreciation. Assets are depreciated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows: % Computers 33 Office furniture and equipment 7 Leasehold improvements 10 Laboratory equipment 15-33
Impairment of non-financial assets	h. Impairment of non-financial assets The long-lived assets of the Company are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2018, 2017, and 2016, no impairment losses have been identified.
Stock-based compensation	i. Stock-based compensation The Company recognizes equity-based compensation expenses for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with FASB ASC Topic 718, Stock Compensation ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The option pricing model requires a number of assumptions. There is no active external or internal market for the Company's common shares, consequently the Company utilized third-party valuations to estimate the fair value of its Ordinary Shares. For the estimation of the expected volatility of the Company's share price, the Company used the historical volatility of comparable companies in the industry with characteristics similar to the Company, including stage of product development and focus on the life science industry. The expected term of options granted represents the period of time that options granted are expected to be outstanding, the company uses management's estimates for the expected term of options due to insufficient readily available historical exercise data. The risk-free interest rate is based on the yield rates of U.S. Government Treasury Bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The Company accounts for stock options issued to non-employees in accordance with ASC Topic 505-50 "Equity -Based Payment to Non-Employees" and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Share-based awards to non-employees are remeasured at each reporting date and compensation costs are recognized as services are rendered. The Company believes that the fair value of these awards is more reliably measurable than the fair value of the services rendered.
Employees benefits	j. Employees benefits Post-employment benefits - Short term employee benefits
Revenue Recognition	k. Revenue Recognition The Company has not yet generated any revenue from product sales.
Research and development expenses	l. Research and development expenses Research and development expenses are charged to the statement of operations and comprehensive loss as incurred and consist of salaries, stock-based compensation, benefits and other personnel-related costs, fees paid to consultants, clinical trials, patent costs and facilities and overhead costs. As of December 31, 2018, the Company has not yet capitalized development expenses.
Patents	m. Patents The Company expenses all costs associated with patents for product candidates under development as incurred. As a result of the Company's research and development efforts, the Company is applying for a number of patents to protect proprietary technology and inventions. To date, the Company has not capitalized patent costs. The Company has recorded a charge to operations of approximately $242, $219 and $87 for the years ended December 31, 2018, 2017 and 2016, respectively, related to its patents' costs.
Income taxes	n. Income taxes The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes". This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. As the Company is currently engaged primarily in development activities and is not expected to generate taxable income in the foreseeable future, the Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2018, the Company provided a liability of $222, see note 5, for uncertain tax positions related to tax withholding matters from prior years. The Company does not expect that the amounts of uncertain tax positions will change significantly within the next year.
Loss per share	o. Loss per share Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, "Earnings per Share." All outstanding preferred stock, options and warrants for the years ended December 31, 2018, 2017 and 2016 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all years presented. For the years ended December 31, 2018, 2017 and 2016 the total weighted average number of shares related to outstanding potential shares excluded from the calculations of diluted net loss per share were 8,638,789, 4,926,621and 3,707,654, respectively. The following data shows the amounts used in computing income (loss) per share and the effect on income (loss): Year ended December 31, Basic and diluted (loss) per share: 2018 2017 2016 (Loss) income from continuing operations $ (4,242 ) $ (2,503 ) $ (2,878 ) Interest on convertible notes - (67 ) Interest of 6% to Cumulative Preferred Stock (659 ) (717 ) (497 ) $ (4,901 ) $ (3,220 ) $ (3,442 ) Number of common shares at the beginning of the year 3,509,344 3,390,733 3,068,184 Stock options exercised 2 - 3,958 Common shares issued in connection with conversion of convertible notes - 35,192 285,505 Number of shares used in per share computation 3,509,346 3,425,925 3,357,647 Basic net income (loss) per share $ (1.40 ) $ (0.94 ) $ (1.03 )
Concentrations of credit risk	p. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash. Cash and cash equivalents are invested in major banks in Israel. Such deposits in Israel are not insured. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company has no foreign exchange contracts or any other hedging arrangements.
Fair value of financial instruments	q. Fair value of financial instruments The Company applies ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. The financial instruments presented on the balance sheet at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - inputs other than quoted prices included within level 1 that are observable either directly or indirectly. Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). The Company's warrants exercisable into shares liability are classified as level 3 in the fair value hierarchy, and measured at fair value on a recurring basis.
Comprehensive income (loss)	r. Comprehensive income (loss) Comprehensive loss is the change in stockholders' equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general purpose financial statements. The Company's other comprehensive income (loss) is currently comprised of gains or losses resulting from translation adjustments which result from translating the Company's financial statements into U.S. dollars when its functional currency is different than the U.S. dollar.
New standards and interpretations	s. New standards and interpretations In February 2018, the FASB issued ASU 2018-02, I ncome Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In May 2017, the FASB issued ASU No. 2017-09, Compensation (Topic 718) In August 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of dollar exchange rate	U.S. $ Exchange rate In Points (*) 1 $ = NIS At the end of: 2018 101.2 3.748 2017 100.4 3.467 2016 100.0 3.845 Increase (decrease) during the year: 2018 0.8 % 8.1 % 2017 0.4 % (9.8 )% 2016 (1.2 )% (1.5 )% (*) Based on the Index for December of each year, on the basis of 2016 Index = 100 points.
Schedule of annual depreciation rates	% Computers 33 Office furniture and equipment 7 Leasehold improvements 10 Laboratory equipment 15-33
Schedule of computing income (loss) per share and the effect on income (loss)	Year ended December 31, Basic and diluted (loss) per share: 2018 2017 2016 (Loss) income from continuing operations $ (4,242 ) $ (2,503 ) $ (2,878 ) Interest on convertible notes - (67 ) Interest of 6% to Cumulative Preferred Stock (659 ) (717 ) (497 ) $ (4,901 ) $ (3,220 ) $ (3,442 ) Number of common shares at the beginning of the year 3,509,344 3,390,733 3,068,184 Stock options exercised 2 - 3,958 Common shares issued in connection with conversion of convertible notes - 35,192 285,505 Number of shares used in per share computation 3,509,346 3,425,925 3,357,647 Basic net income (loss) per share $ (1.40 ) $ (0.94 ) $ (1.03 )

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents	December 31, 2018 2017 Cash held in banks $ 1,029 $ 498 Bank deposits in U.S.$ (annual average interest rates 1.81% and 1.37%) 8,707 8,507 $ 9,736 $ 9,005

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, 2018 2017 Cost: Laboratory equipment $ 797 $ 533 Computers 86 80 Office furniture & equipment 58 55 Leasehold improvements 228 126 1,169 794 December 31, 2018 2017 Accumulated depreciation: Laboratory equipment 331 266 Computers 62 51 Office furniture & equipment 13 10 Leasehold improvements 78 79 484 406 Depreciated cost $ 685 $ 388

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Schedule of accrued expenses and other liabilities	December 31, 2018 2017 Vacation, convalescence and bonus accruals $ 211 $ 133 Employees and payroll related 158 104 Tax provision for uncertain tax position 222 240 Accrued expenses and other 353 157 $ 944 $ 634

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Series B Preferred Stock and warrants exercisable into shares of Series B Preferred Stock	Year ended December 31, 2018 2017 Balance at January 1 $ 344 $ - Exchange differences arising from translation to presentation currency (20 ) Fair value of warrants at issuance date 344 Changes in values of warrants exercisable into shares liability (132 ) - Balance at December 31 $ 192 $ 344
Schedule of fair value of warrants granted using the OPM pricing model	Year ended December 31, 2018 2017 Dividend yield - - Expected yearly volatility 75.8 % 75.83 % Annual risk-free interest 2.74 % 1.39 % Expected life 1 month 2 years

Commitments and contingent li_2

Commitments and contingent liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of minimum lease commitments under operating leases	2019 $ 185 2020 115 2021 97 2022 83 2023 62 $ 542

Transactions with Related Par_2

Transactions with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Schedule of benefits to related parties	Year ended December 31, 2018 2017 2016 Benefits to related parties: Compensation to non-employees directors $ - $ - $ 21 Share based Compensation to non-employees directors $ 73 $ (29 ) 47 Other related parties expenses $ 50 $ - $ - Other Comprehensive loss - interest on convertible notes $ - $ - $ 67
Schedule of key management compensation	Year ended December 31, 2018 2017 2016 Salaries and employee benefits $ 500 $ 517 $ 520 Share-based compensation 745 51 62 $ 1,245 $ 568 $ 582

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Schedule of issuance of preferred stock and warrants exercisable	Shares of Series B Preferred Stock $ 7,730 Issuance costs allocated to Preferred Stock 519 8,249 Fair value attributed to the investors' warrants 301 $ 8,550

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Schedule of share-based compensation expenses related to grants under the Equity Incentive Plan	Year ended December 31, 2018 2017 2016 Research & development $ 862 $ 123 $ 21 General & administrative 147 (2 ) 90 Total $ 1,009 $ 121 $ 111
Schedule of exercise prices and remaining contractual life	exercise price Number of options outstanding Remaining contractual Life (in years) No. of options exercisable $ 1.86 533 0.8 533 $ 2.69 736,034 6.0 668,382 $ 2.69 35,895 1.5 35,895 $ 2.69 7,310 7.2 3,655 $ 2.69 137,814 8.2 132,440 $ 2.69 16,622 9.0 16,622 $ 6.22 561,966 9.0 169,115 $ 6.22 73,504 9.1 - $ 6.22 53,192 9.6 - $ 6.22 3,147 9.7 - $ 6.22 108,928 9.8 - $ 2.69 49,867 9.8 - $ 10.12 2,421 9.9 - $ 6.22 14,185 9.9 - 1,801,418 1,026,642
Employee Stock Option [Member]
Schedule of fair value of stock option weighted-average assumptions	Year ended December 31, 2018 2017 2016 Weighted Average Risk-free interest rate 2.88 % 2.25 % 1.34 % Dividend yield - - - Weighted Average Volatility factor 74.91 % 73.31 % 72.57 % Weighted Average Expected life of the options 6 6 6
Summary of changes in nonvested shares granted	For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Balance at beginning of the year 730,899 $ 5.37 309,999 $ 2.69 444,241 $ 2.69 Granted 271,355 $ 5.78 590,839 $ 5.78 11,667 $ 2.69 Vested during the year (217,733 ) $ 4.75 (102,724 ) $ 2.69 (115,278 ) $ 2.69 Forfeited during the year (159,219 ) $ 5.16 (67,215 ) $ 2.69 (30,631 ) $ 2.69 Balance at end of the year 625,302 $ 5.58 730,899 $ 5.37 309,999 $ 2.69
Schedule of options granted to employees and directors under the existing stock-option plans	For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of the year 974,272 $ 4.54 453,973 $ 2.69 483,482 $ 2.69 Granted 271,355 $ 5.78 590,839 $ 5.78 11,667 $ 2.69 Forfeited and expired (162,543 ) $ 4.96 (70,540 ) $ 2.69 (30,631 ) $ 2.69 Exercised (61 ) $ 2.69 - $ - (10,545 ) $ 2.69 Outstanding at end of the year 1,083,023 $ 4.75 974,272 $ 4.54 453,973 $ 2.69 Exercisable at end of the year 457,721 $ 3.72 243,373 $ 2.69 143,974 $ 2.69
Consultants stock options [Member]
Schedule of fair value of stock option weighted-average assumptions	Year ended December 31, 2018 2017 2016 Weighted Average Risk-free interest rate 2.55 % 2.25 % - Dividend yield - - - Weighted Average Volatility factor 75.23 % 73.31 % - Weighted Average Expected life of the options 6 6 -
Summary of changes in nonvested shares granted	For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Balance at beginning of the year 154,920 $ 6.20 - $ - 398,937 $ 2.69 Granted 33,889 $ 6.40 285,569 $ 4.54 - $ - Vested during the year (39,335 ) $ 6.20 (130,649 ) $ 2.69 (398,937 ) $ 2.69 Forfeited during the year - $ - - $ - - $ - Balance at end of the year 149,474 $ 6.20 154,920 $ 6.20 - $ -
Schedule of options granted to employees and directors under the existing stock-option plans	For the year ended December 31, 2018 2017 2016 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of the year 684,506 $ 3.51 398,937 $ 2.69 398,937 $ 2.69 Granted 33,889 $ 6.40 285,569 $ 4.54 - $ - Forfeited and expired - $ - - $ - - $ - Exercised - $ - - $ - - $ - Outstanding at end of the year 718,395 $ 3.72 684,506 $ 3.51 398,937 $ 2.69 Exercisable at end of the year 568,921 $ 2.89 529,586 $ 2.69 398,937 $ 2.69

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes	Year ended December 31, 2018 2017 2016 Current tax $ - $ - $ - Deferred tax - - - Provision for income taxes, net $ - $ - $ -
Schedule of reconciliation of the theoretical tax expenses	Year ended December 31, 2018 2017 2016 Loss before taxes $ 4,242 $ 2,503 $ 2,878 Statutory tax rate 23 % 24 % 25 % Tax benefit 976 601 719 Permanent differences (237 ) (30 ) (28 ) Valuation allowance (778 ) (501 ) (652 ) Differences in tax rate - (36 ) (65 ) Translation differences 39 (34 ) 26 Tax expenses $ - $ - $ -
Schedule of deferred tax liabilities and assets	Year ended December 31, 2018 2017 2016 Tax assets in respect of: $ $ $ Accrued employees benefits 31 18 17 Research and development expenses 615 379 414 Net loss carry forward 2,771 2,242 1,707 Total deferred tax assets 3,417 2,639 2,138 Less - valuation allowance (3,417 ) (2,639 ) (2,138 ) Deferred tax assets $ - $ - $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Schedulr of financial assets measured at fair value on a recurring basis	December 31, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 9,736 $ 9,736 $ - $ - Short term deposits 40 40 - - Restricted cash 56 56 - - Total financial assets $ 9,832 $ 9,832 $ - $ - Warrants $ 192 $ - $ - $ 192 Total financial liabilities $ 192 $ - $ - $ 192 December 31, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 9,005 $ 9,005 $ - $ - Restricted cash 27 27 - - Total financial assets $ 9,032 $ 9,032 $ - $ - Warrants $ 344 $ - $ - $ 344 Total financial liabilities $ 344 $ - $ - $ 344 December 31, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,020 $ 3,020 $ - $ - Restricted cash 25 25 - - Total financial assets $ 3,045 $ 3,045 $ - $ -

Supplementary Financial State_2

Supplementary Financial Statement Information (Tables)	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of condensed income statement	a. Research and development expenses – net Year ended December 31, 2018 2017 2016 Payroll and related expenses $ 1,317 $ 593 $ 732 Research and development services 1,237 493 832 Patent-related expenses 242 219 87 Share Based Compensation 862 123 21 Depreciation 121 83 58 Other 476 180 203 4,255 1,691 1,933 Israel Innovation Authority participation in research and development costs and royalties payable - - 96 $ 4,255 $ 1,691 $ 2,029 b. General and administrative expenses Year ended December 31, 2018 2017 2016 Payroll expenses and management fees $ 525 $ 365 $ 373 Professional fees 208 70 211 Office maintenance and other 108 23 96 Share Based Compensation 147 (2 ) 90 Travel Expenses 57 24 23 $ 1,045 $ 480 $ 793 c. Financial income Year ended December 31, 2018 2017 2016 Interest income $ 138 $ 37 $ 30 Exchange differences, net 790 - - Net change in fair value warrants 132 - - $ 1,060 $ 37 $ 30 d. Financial expenses Year ended December 31, 2018 2017 2016 Issuance expenses related to warrants $ - $ 19 $ - Exchange differences, net - 350 84 Bank commissions 3 1 2 $ 3 $ 370 $ 86

Financial income, net (Tables)

Financial income, net (Tables)	12 Months Ended
	Dec. 31, 2018
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Financial income, net are as follows: Year Ended December 31, 2017 2016 2015 U.S. dollars in thousands Interest income $ 39 $ 90 $ 186 Gain (loss) on foreign currency transactions, net 4 (22) (39) Other expenses (5) (8) (12) Total $ 38 $ 60 $ 135

General Information (Details)

General Information (Details) $ in Thousands	1 Months Ended
	Mar. 25, 2019	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
General [Line Items]
Accumulated deficit		$ (16,289)	$ (12,047)
Subsequent Event [Member]
General [Line Items]
Equity issued and outstanding	96.00%
Ordinary share and option	0.04841

Significant Accounting Polici_4

Significant Accounting Policies (Details)	Dec. 31, 2018
2018 [Member]
At the end of:
In Points	101.2	[1]
U.S. $ Exchange rate 1 $ = NIS	3.748
Increase (decrease) during the year:
In Points	0.80%	[1]
U.S. $ Exchange rate 1 $ = NIS	8.10%
2017 [Member]
At the end of:
In Points	100.4	[1]
U.S. $ Exchange rate 1 $ = NIS	3.467
Increase (decrease) during the year:
In Points	0.40%	[1]
U.S. $ Exchange rate 1 $ = NIS	(9.80%)
2016 [Member]
At the end of:
In Points	100	[1]
U.S. $ Exchange rate 1 $ = NIS	3.845
Increase (decrease) during the year:
In Points	(1.20%)	[1]
U.S. $ Exchange rate 1 $ = NIS	(1.50%)
[1]	Based on the Index for December of each year, on the basis of 2016 Index = 100 points.

Significant Accounting Polici_5

Significant Accounting Policies (Details 1)	Dec. 31, 2018
Computers [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Annual depreciation rates	33.00%
Office furniture and equipment [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Annual depreciation rates	7.00%
Leasehold improvements [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Annual depreciation rates	10.00%
Laboratory equipment [Member] | Minimum [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Annual depreciation rates	15.00%
Laboratory equipment [Member] | Maximum [Member]
SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Annual depreciation rates	33.00%

Significant Accounting Polici_6

Significant Accounting Policies (Details 2) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Basic and diluted (loss) per share:
(Loss) income from continuing operations	$ (4,242)	$ (2,503)	$ (2,878)
Interest on convertible notes			(67)
Interest of 6% to Cumulative Preferred Stock	(659)	(717)	(497)
Total	$ (4,901)	$ (3,220)	$ (3,442)
Number of common shares at the beginning of the year	3,509,344	3,390,733	3,068,184
Stock options exercised	2		3,958
Common shares issued in connection with conversion of convertible notes		35,192	285,505
Number of shares used in per share computation	3,509,346	3,425,925	3,357,647
Basic net income (loss) per share	$ (1.40)	$ (0.94)	$ (1.03)

Significant Accounting Polici_7

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2019
Summary of Significant Accounting Policies (Textual)
Percentage of deposits rate	8.33%
Related to its patents' costs	$ 242	$ 219	$ 87
Liability of uncertain tax positions related to tax	$ 222
Weighted average number of shares related to outstanding potential shares	8,638,789	4,926,621	3,707,654
Subsequent Event [Member]
Summary of Significant Accounting Policies (Textual)
Right-of-use assets and lease liabilities				$ 458

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash held in banks	$ 1,029	$ 498
Bank deposits in U.S.$ (annual average interest rates 1.81% and 1.37%)	8,707	8,507
Total	$ 9,736	$ 9,005	$ 3,020	$ 262

Cash and Cash Equivalents (De_2

Cash and Cash Equivalents (Details Textual)	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents (Textual)
Annual average interest rates	1.81%	1.37%

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Cost	$ 1,169	$ 794
Accumulated depreciation	484	406
Depreciated cost	685	388
Laboratory equipment [Member]
Cost	797	533
Accumulated depreciation	331	266
Computers [Member]
Cost	86	80
Accumulated depreciation	62	51
Office furniture & equipment [Member]
Cost	58	55
Accumulated depreciation	13	10
Leasehold improvements [Member]
Cost	228	126
Accumulated depreciation	$ 78	$ 79

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property and Equipment (Textual)
Depreciation expenses	$ 121	$ 83	$ 58

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Vacation, convalescence and bonus accruals	$ 211	$ 133
Employees and payroll related	158	104
Tax provision for uncertain tax position	222	240
Accrued expenses and other	353	157
Accrued expenses and other liabilities, Total	$ 944	$ 634

Warrants (Details)

Warrants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance	$ 344
Exchange differences arising from translation to presentation currency	(20)
Fair value of warrants at issuance date		344
Changes in values of warrants exercisable into shares liability	(132)
Balance	$ 192	$ 344

Warrants (Details 1)

Warrants (Details 1)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Dividend yield
Expected yearly volatility	75.80%	75.83%
Annual risk-free interest	2.74%	1.39%
Expected life	1 month	2 years

Commitments and Contingent Li_3

Commitments and Contingent Liabilities (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 185
2020	115
2021	97
2022	83
2023	62
Total operating leases	$ 542

Commitments and Contingent Li_4

Commitments and Contingent Liabilities (Details Textual) ₪ in Thousands, $ in Thousands	1 Months Ended				12 Months Ended
	Jul. 30, 2018USD ($)ft²	Jul. 30, 2018ILS (₪)	Sep. 17, 2015USD ($)ft²	Sep. 17, 2015ILS (₪)	Dec. 31, 2018USD ($)	Jul. 30, 2018ILS (₪)ft²	Sep. 17, 2015ILS (₪)ft²
Commitments and contingent liabilities (Textual)
Percentage of grants					100.00%
Aggregate contingent obligation					$ 3,973
Ness Ziona [Member]
Commitments and contingent liabilities (Textual)
Offices and laboratory space | ft²	420					420
Rental agreement period	5 years	5 years
Additional rental agreement period	5 years	5 years
Rental and management fees	$ 7
Lessor bank guarantee amount	$ 31
NIS [Member] | Ness Ziona [Member]
Commitments and contingent liabilities (Textual)
Rental and management fees | ₪		₪ 26
Lessor bank guarantee amount | ₪						₪ 115
Hadassah University Hospital [Member]
Commitments and contingent liabilities (Textual)
Offices and laboratory space | ft²			283				283
Rental agreement period			4 years	4 years
Additional rental agreement period			4 years	4 years
Rental and management fees			$ 6
Lessor bank guarantee amount			$ 20
Hadassah University Hospital [Member] | NIS [Member]
Commitments and contingent liabilities (Textual)
Rental and management fees | ₪				₪ 22
Lessor bank guarantee amount | ₪							₪ 75
Minimum [Member]
Commitments and contingent liabilities (Textual)
Percentage of royalties in sales					3.00%
Maximum [Member]
Commitments and contingent liabilities (Textual)
Percentage of royalties in sales					5.00%

Transactions with Related Par_3

Transactions with Related Parties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Compensation to non-employees directors [Member]
Benefits to related parties
Expenses (income)			$ 21
Share based Compensation to non-employees directors [Member]
Benefits to related parties
Expenses (income)	73	(29)	47
Other related parties expenses [Member]
Benefits to related parties
Expenses (income)	50
Other Comprehensive loss - interest on convertible notes [Member]
Benefits to related parties
Expenses (income)			$ 67

Transactions with Related Par_4

Transactions with Related Parties (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Key management compensation	$ 1,245	$ 568	$ 582
Salaries and employee benefits [Member]
Key management compensation	500	517	520
Share-based compensation [Member]
Key management compensation	$ 745	$ 51	$ 62

Equity (Details)

Equity (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Oct. 20, 2017	Sep. 15, 2017	Dec. 31, 2018	Dec. 31, 2017
Shares of Series B Preferred Stock				$ 7,730
Issuance costs			$ 156	519
Cash consideration			5,350	$ 8,249
Series B Preferred Stock [Member]
Shares of Series B Preferred Stock			7,730
Issuance costs			519
Cash consideration			8,249
Fair value attributed to the investors’ warrants			301
Total	$ 8,550	$ 8,550	$ 8,550

Equity (Details Textual)

Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 01, 2016	Sep. 12, 2018	Oct. 20, 2017	Sep. 15, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 14, 2017
Equity (Textual)
Original issue price per annum					6.00%
Unpaid dividends to Convertible Preferred Stock holders					$ 1,872	$ 1,213	$ 496
Issuance of preferred stock, shares					23,182
Issuance costs					$ 156	519
Warrants exercisable			1,773,398	1,773,398
Warrants exercised, description					(i) post the consummation of a public listing of the Company's shares on an Asian-Pacific stock exchange, with aggregate proceeds of at least $25,000 and a price per share reflecting a company pre-money Company valuation of at least $200,000; (ii) post the consummation of an M&A transaction with a Asian-Pacific company reflecting a Company valuation of at least $200,000; or (iii) post the closing of a licensing agreement between the Company and an Asian-Pacific party that provides for an initial payment to the Company of at least $25,000. (together, i, ii and iii, the "Exercise Event").
Warrants exercise price					$ 6.22
Adjustments of warrant maturity					7 years
Additional issuance costs					$ 37
Conversion of warrants					1
Term, description					The warrants will expire at the earlier of 36 months from the issuance date or an Exercise Event as defined in the warrant agreements.
Preferred stock, shares issued	3,059,730
Issuance of Common and Preferred Stock in connection with conversion of Convertible Notes and accrued interest	$ 8,865					$ 7	$ 8,865
Warrant [Member]
Equity (Textual)
Issuance costs					$ 19
Common Stock [Member]
Equity (Textual)
Preferred stock, shares issued	312,004							118,611
Series C Preferred Stock [Member]
Equity (Textual)
Issuance of preferred stock, shares		520,263			4,908
Cash consideration		$ 5,300			$ 50
Preferred stock, shares issued					525,171	525,171
Series B Preferred Stock [Member]
Equity (Textual)
Issuance of preferred stock, shares			1,373,804	1,373,804
Cash consideration			$ 8,550	$ 8,550	$ 8,550
Issuance costs					$ 519
Warrants exercisable					48,204
Warrants exercised, description					6.22
Preferred stock, shares issued					1,373,804	1,373,804
Series B Preferred Stock [Member] | Warrant [Member]
Equity (Textual)
Issuance costs					$ 538

Share-Based Compensation (Detai

Share-Based Compensation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employees’ and directors stock options [Member]
Weighted Average Risk-free interest rate	2.88%	2.25%	1.34%
Dividend yield
Weighted Average Volatility factor	74.91%	73.31%	72.57%
Weighted Average Expected life of the options	6 years	6 years	6 years
Consultants stock options [Member]
Weighted Average Risk-free interest rate	2.55%	2.25%
Dividend yield
Weighted Average Volatility factor	75.23%	73.31%
Weighted Average Expected life of the options	6 years	6 years	0 years

Share-Based Compensation (Det_2

Share-Based Compensation (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of options, Outstanding at end of the year	1,801,418
Number of options, Exercisable at end of the year	1,026,642
Consultants’ stock options [Member]
Number of options, Outstanding at beginning of the year	684,506	398,937	398,937
Number of options, Granted	33,889	285,569
Number of options, Forfeited/Expired
Number of options, Exercised
Number of options, Outstanding at end of the year	718,395	684,506	398,937
Number of options, Exercisable at end of the year	568,921	529,586	398,937
Weighted average exercise price, Outstanding at beginning of the year	$ 3.51	$ 2.69	$ 2.69
Weighted average exercise price, Granted	6.40	4.54
Weighted average exercise price, Exercised
Weighted average exercise price, Forfeited/Expired
Weighted average exercise price, Outstanding at beginning of the year	3.72	3.51	2.69
Weighted average exercise price, Exercisable at end of the year	$ 2.89	$ 2.69	$ 2.69
Weighted-Average Remaining Contractual Term (Years)	2 years 10 months 25 days
Employee Stock Option [Member]
Number of options, Outstanding at beginning of the year	974,272	453,973	483,482
Number of options, Granted	271,355	590,839	241,000
Number of options, Forfeited/Expired	(162,543)	(70,540)	(632,708)
Number of options, Exercised	(61)		(217,816)
Number of options, Outstanding at end of the year	1,083,023	974,272	453,973
Number of options, Exercisable at end of the year	457,721	243,373	143,974
Weighted average exercise price, Outstanding at beginning of the year	$ 4.54	$ 2.69	$ 2.69
Weighted average exercise price, Granted	5.78	5.78	2.69
Weighted average exercise price, Exercised	2.69		2.69
Weighted average exercise price, Forfeited/Expired	4.96	2.69	2.69
Weighted average exercise price, Outstanding at beginning of the year	4.75	4.54	2.69
Weighted average exercise price, Exercisable at end of the year	$ 3.72	$ 2.69	$ 2.69

Share-Based Compensation (Det_3

Share-Based Compensation (Details 2)	12 Months Ended
	Dec. 31, 2018$ / shares₪ / sharesshares	Dec. 31, 2017$ / shares₪ / sharesshares	Dec. 31, 2016$ / shares₪ / sharesshares
Employee Stock Option [Member]
Number of options, Balance at beginning of the year	730,899	309,999	444,241
Number of options, Granted	271,355	590,839	11,667
Number of options, Vested during the year	(217,733)	(102,724)	(115,278)
Number of options, Forfeited during the year	(159,219)	(67,215)	(30,631)
Number of options, Balance at end of the year	625,302	730,899	309,999
Weighted average exercise price, Balance at beginning of the year | ₪ / shares	₪ 5.37	₪ 2.69	₪ 2.69
Weighted average exercise price, Granted | $ / shares	₪ 5.78	₪ 5.78	₪ 2.69
Weighted average exercise price, Vested during the year | $ / shares	4.75	2.69	2.69
Weighted average exercise price, Forfeited during the year | $ / shares	₪ 5.16	₪ 2.69	₪ 2.69
Weighted average exercise price, Balance at end of the year | ₪ / shares	₪ 5.37	₪ 2.69	₪ 2.69
Consultants’ stock options [Member]
Number of options, Balance at beginning of the year	154,920		398,937
Number of options, Granted	33,889	285,569
Number of options, Vested during the year	(39,335)	(130,649)	(398,937)
Number of options, Forfeited during the year
Number of options, Balance at end of the year	149,474	154,920
Weighted average exercise price, Balance at beginning of the year | ₪ / shares	₪ 6.20		₪ 2.69
Weighted average exercise price, Granted | $ / shares	₪ 6.40	₪ 4.54
Weighted average exercise price, Vested during the year | $ / shares	6.20	2.69	2.69
Weighted average exercise price, Forfeited during the year | $ / shares
Weighted average exercise price, Balance at end of the year | ₪ / shares	₪ 6.20		₪ 2.69

Share-Based Compensation (Det_4

Share-Based Compensation (Details 3)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of options outstanding	1,801,418
No. of options exercisable	1,026,642
Exercise Price One [Member] | Option [Member]
Number of options outstanding	533
Remaining contractual Life (in years)	9 months 18 days
No. of options exercisable	533
Exercise price | $ / shares	$ 1.86
Exercise Price Two [Member] | Option [Member]
Number of options outstanding	736,034
Remaining contractual Life (in years)	6 years
No. of options exercisable	668,382
Exercise price | $ / shares	$ 2.69
Exercise Price Three [Member] | Option [Member]
Number of options outstanding	35,895
Remaining contractual Life (in years)	1 year 6 months
No. of options exercisable	35,895
Exercise price | $ / shares	$ 2.69
Exercise Price Four [Member] | Option [Member]
Number of options outstanding	7,310
Remaining contractual Life (in years)	7 years 2 months 12 days
No. of options exercisable	3,655
Exercise price | $ / shares	$ 2.69
Exercise Price Five [Member] | Option [Member]
Number of options outstanding	137,814
Remaining contractual Life (in years)	8 years 2 months 12 days
No. of options exercisable	132,440
Exercise price | $ / shares	$ 2.69
Exercise Price Six [Member] | Option [Member]
Number of options outstanding	16,622
Remaining contractual Life (in years)	9 years
No. of options exercisable	16,622
Exercise price | $ / shares	$ 2.69
Exercise Price Seven [Member] | Option [Member]
Number of options outstanding	561,966
Remaining contractual Life (in years)	9 years
No. of options exercisable	169,115
Exercise price | $ / shares	$ 6.22
Exercise Price Eight [Member] | Option [Member]
Number of options outstanding	73,504
Remaining contractual Life (in years)	9 years 1 month 6 days
No. of options exercisable
Exercise price | $ / shares	$ 6.22
Exercise Price Nine [Member] | Option [Member]
Number of options outstanding	5,319
Remaining contractual Life (in years)	9 years 7 months 6 days
No. of options exercisable
Exercise price | $ / shares	$ 6.22
Exercise Price Ten [Member] | Option [Member]
Number of options outstanding	3,147
Remaining contractual Life (in years)	9 years 8 months 12 days
No. of options exercisable
Exercise price | $ / shares	$ 6.22
Exercise Price Eleven [Member] | Option [Member]
Number of options outstanding	108,928
Remaining contractual Life (in years)	9 years 9 months 18 days
No. of options exercisable
Exercise price | $ / shares	$ 6.22
Exercise Price Twelve [Member] | Option [Member]
Number of options outstanding	49,867
Remaining contractual Life (in years)	9 years 9 months 18 days
No. of options exercisable
Exercise price | $ / shares	$ 2.69
Exercise Price Thirteen [Member] | Option [Member]
Number of options outstanding	2,421
Remaining contractual Life (in years)	9 years 10 months 25 days
No. of options exercisable
Exercise price | $ / shares	$ 10.12
Exercise Price Fourteen [Member] | Option [Member]
Number of options outstanding	14,185
Remaining contractual Life (in years)	9 years 10 months 25 days
No. of options exercisable
Exercise price | $ / shares	$ 6.22

Share-Based Compensation (Det_5

Share-Based Compensation (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation	$ 1,009	$ 121	$ 111
Research & development [Member]
Share-based Compensation	862	123	21
General & administrative [Member]
Share-based Compensation	$ 147	$ (2)	$ 90

Share-Based Compensation (Det_6

Share-Based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-Based Compensation (Textual)
Authorized shares issuance to its employees, director and consultants	23,182
Weighted-average fair value at grant date of the options granted	$ 5.78	$ 0.207	$ 0.826
The total intrinsic value of options granted and options exercised	$ 963	$ 0
Employee Stock Option [Member]
Share-Based Compensation (Textual)
Total unrecognized estimated compensation cost	$ 1,274
Weighted average period	1 year 9 months 25 days
Consultants' stock options [Member]
Share-Based Compensation (Textual)
Total unrecognized estimated compensation cost	$ 690
Weighted average period	2 years 10 months 25 days
2007 Incentive Compensation Plan [Member]
Share-Based Compensation (Textual)
Authorized shares issuance to its employees, director and consultants	48,466
2014 Equity Incentive Plan [Member]
Share-Based Compensation (Textual)
Authorized shares issuance to its employees, director and consultants	1,835,204

Taxes on Income (Details)

Taxes on Income (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Current tax
Deferred tax
Provision for income taxes, net

Taxes on Income (Details 1)

Taxes on Income (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Loss before taxes	$ 4,242	$ 2,503	$ 2,878
Statutory tax rate	23.00%	24.00%	25.00%
Tax benefit	$ 976	$ 601	$ 719
Permanent differences	(237)	(30)	(28)
Valuation allowance	(778)	(501)	(652)
Differences in tax rate		(36)	(65)
Translation differences	39	(34)	26
Tax expenses

Taxes on Income (Details 2)

Taxes on Income (Details 2) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Tax assets in respect of:
Accrued employees benefits	$ 31	$ 18	$ 17
Research and development expenses	615	379	414
Net loss carry forward	2,771	2,242	1,707
Total deferred tax assets	3,417	2,639	2,138
Less - valuation allowance	(3,417)	(2,639)	(2,138)
Deferred tax assets

Taxes on Income (Details Textua

Taxes on Income (Details Textual) - USD ($) $ in Thousands	Jan. 02, 2018	Jan. 02, 2017	Dec. 31, 2016	Dec. 31, 2018
Taxes on Income (Textual)
Israeli corporate tax rate	23.00%	24.00%	25.00%
Carry-forwards losses				$ 12,050

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 9,736	$ 9,005	$ 3,020
Short term deposits	40
Restricted cash	56	27	25
Total financial assets	9,832	9,032	3,045
Warrants	192	344
Total financial liabilities	192	344
Level 1 [Member]
Cash and cash equivalents	9,736	9,005	3,020
Short term deposits	40
Restricted cash	56	27	25
Total financial assets	9,832	9,032	3,045
Warrants
Total financial liabilities
Level 2 [Member]
Cash and cash equivalents
Short term deposits
Restricted cash
Total financial assets
Warrants
Total financial liabilities
Level 3 [Member]
Cash and cash equivalents
Short term deposits
Restricted cash
Total financial assets
Warrants	192	344
Total financial liabilities	$ 192	$ 344

Supplementary Financial State_3

Supplementary Financial Statement Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Research and development expenses – net
Payroll and related expenses	$ 1,317	$ 593	$ 732
Research and development services	1,237	493	832
Patent-related expenses	242	219	87
Share Based Compensation	862	123	21
Depreciation	121	83	58
Other	476	180	203
Research and development expenses, gross	4,255	1,691	1,933
Israel Innovation Authority participation in research and development costs and royalties payable			96
Research and development expenses – net	4,255	1,691	2,029
General and administrative expenses
Payroll expenses and management fees	525	365	373
Professional fees	208	70	211
Office maintenance and other	108	23	96
Share Based Compensation	147	(2)	90
Travel Expenses	57	24	23
General and administrative expenses	1,044	480	793
Financial income
Interest income	138	37	30
Exchange differences, net	790
Net change in fair value warrants	132
Financial income	1,060	37	30
Financial expenses
Issuance expenses related to warrants		19
Exchange differences, net		350	84
Bank commissions	3	1	2
Financial expenses	$ 3	$ 370	$ 86